FMP
ESSA Pharma Inc.
EPIX
NASDAQ
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
1.86 USD
0.03 (1.61%)
We are unable to load the chart at this time.
Date
Revenue
Earnings
Estimated Earnings
Surprise
2024-12-17
0
-0.14
-0.19
-26.32%
2024-08-05
0
-0.16
-0.26
-38.46%
2024-05-14
0
-0.2
-0.19
5.26%
2024-02-13
0
-0.14
-0.17
-17.65%
2023-12-12
0
-0.12
-0.22
-45.45%
2023-08-08
0
-0.17
-0.2
-15.00%
2023-05-09
0
-0.16
-0.2
-20.00%
2023-02-07
0
-0.15
-0.24
-37.50%
2022-12-13
0
-0.14
-0.28
-50.00%
2022-08-04
0
-0.2
-0.27
-25.93%
2022-05-10
0
-0.25
-0.25
0.00%
2022-02-03
0
-0.21
-0.23
-8.70%
2021-11-18
0
-0.2
-0.23
-13.04%
2021-08-16
0
-0.21
-0.26
-19.23%
2021-05-06
0
-0.36
-0.21
71.43%
2021-02-11
0
-0.2
-0.17
17.65%
2020-12-15
0
-0.17
-0.2
-15.00%
2020-08-06
0
-0.24
-0.29
-17.24%
2020-05-07
0
-0.45
-0.2
125.00%
2020-02-13
0
-0.22
-0.17
29.41%
2019-12-19
0
-0.06
-0.15
-60.00%
2019-08-14
0
-0.52
-0.54
-3.70%
2019-05-10
0
-0.54
-0.44
22.73%
2019-02-07
0
-0.42
0
-
2018-12-13
0
-0.39
-0.43
-9.30%
2018-08-14
0
-0.5
-0.74
-32.43%
2018-05-14
0
-0.83
-0.4
107.50%
2018-02-13
0
-1.4
0
-
2017-12-11
0
-1.8
-1.23
46.70%
2017-08-14
0
-3.2
-3.4
-5.88%
2017-05-15
0
-5.2
-2.2
136.36%
2017-02-13
0
1
0
-
2016-12-14
217
-3.8
0
-
2016-08-12
0
-2.6
0
-
2016-05-13
0
-4
0
-
2016-02-12
0
-3.6
-0.17
2017.65%
2015-12-14
0
0.4
-0.07
-671.43%
2015-08-17
0
-0.26
-0.13
100.00%
2015-05-28
0
-0.2
-0.22
-9.09%
2015-02-27
0
-1.64
0
-
2014-09-30
0
-0.6
0
-
2014-06-30
0
-1.25
0
-
2014-03-31
0
-0.18
0
-
2013-12-31
0
-0.29
0
-